Table 2 Comparison of efficacy between PD-1 group and PD-L1 group
|  | PD-1 group | PD-L1 group | p value |
|---|---|---|---|
CR | 1 | 0 | Â |
PR | 53 | 68 | Â |
SD | 9 | 13 | Â |
PD | 5 | 5 | Â |
ORR (%)(CR + PR) | 54 (79.4) | 68 (79.1) | 0.959 |
DCR (%) (CR + PR + SD) | 63 (92.6) | 81 (94.2) | 0.956 |
PFS | Â | Â | Â |
 Events, n (%) | 56 (82.4) | 65 (75.6) |  |
 Median, months (95%CI) | 7.6 (6.936–8.264) | 8.3 (7.717–8.883) | 0.415 |
 6-month rate (95%CI) | 64.7% (53.1–76.3) | 67.4% (57.4–77.4) | 0.853 |
 12-month rate (95%CI) | 26.6% (15.4–37.8) | 34.9% (24.3–45.5) | 0.345 |
 18-month rate (95%CI) | 16.6% (7.2–26.0) | 23.7% (13.7–33.7) | 0.376 |
 24-month rate (95%CI) | 12.1% (3.5–20.7) | 10.4% (0.0-20.8) | 0.997 |
OS | Â | Â | Â |
 Events, n (%) | 40 (58.8) | 46 (53.5) |  |
 Median, months (95%CI) | 26.9 (13.805–39.995) | 25.6 (16.214–34.986) | 0.859 |
 6-month rate (95%CI) | 92.6% (86.3–98.9) | 95.3% (90.8–99.8) | 0.716 |
 12-month rate (95%CI) | 69.0% (58.0–80.0) | 80.1% (71.7–88.5) | 0.161 |
 18-month rate (95%CI) | 54.9% (42.9–66.9) | 56.2% (45.4–67.0) | 0.992 |
 24-month rate (95%CI) | 50.5% (38.0–63.0) | 50.7% (39.1–62.3) | 0.985 |